Leveraging AI to lower drug discovery cost and more briefs
New AI helps lower cost of drug discovery
Australian researchers have developed a new AI tool for drug discovery that decodes protein-molecule interactions without the need for expensive 3D structure rendering.
The tool, called PSICHIC (PhySIcoCHemICal), uses AI to identify distinctive “fingerprints” of specific protein-molecule interactions based solely on sequence data.
In a study published in *Nature Machine Intelligence*, PSICHIC demonstrated its ability to “effectively screen new drug candidates and perform selectivity profiling.” According to Dr. Lauren May, co-lead author from the Monash Institute of Pharmaceutical Sciences, the model was also capable of “distinguishing the functional effects of the compound,” or how it impacts the human body.
Digital twin for ventilation optimisation
Researchers at the University of Canterbury are leveraging digital twin technology to optimize mechanical ventilation.
These digital twins, which incorporate patient data such as sedative requirements, lung pressure, and airflow, are used to “predict whether more pressure, volume, or oxygen will help the patient gain lung volume without causing damage,” explained Geoff Chase, a distinguished professor at the University.
Professor Chase also highlighted that patients requiring ventilation double their daily ICU costs. He noted that “reducing time on a ventilator not only improves patient outcomes but could also save New Zealand an estimated N$17 million ($10 million) annually for each day of reduced ventilation time.”
Novari continues international collabs for advanced patient engagement
Personify Care has partnered with Canada-based Novari Health to offer an integrated healthcare solution.
According to a media release, this collaboration will allow Novari’s referral management software to initiate clinically-defined prehabilitation and pre-admission pathways.
As part of their partnership, the Novari Patient Engage platform, powered by PersonifyCare, will be launched in Canada and the United Kingdom. Additionally, a “fully interoperable offering” combining the two companies’ solutions will be rolled out across Australia and New Zealand.
Earlier in March, Novari Health also teamed up with Australian company Alcidion to provide an integrated solution aimed at improving patient flow management.
